TABLE 2.
Inhibitory activities of T-20-derived lipopeptide fusion inhibitors against divergent HIV-1 subtypesa
| Primary Env | Subtype | Mean IC50 (pM) ± SD |
|||
|---|---|---|---|---|---|
| T-20 | LP-40 | LP-50 | LP-51 | ||
| 92UG037.8 | A | 7,581 ± 2,117 | 3,667 ± 1,040 | 19 ± 6 | 17 ± 4 |
| 92RW020 | A | 3,582 ± 2,682 | 1,279 ± 71 | 37 ± 4 | 56 ± 8 |
| 398-F1_F6_20 | A | 16,913 ± 1,702 | 4,853 ± 1,099 | 12 ± 2 | 15 ± 4 |
| PVO | B | 71,948 ± 3,160 | 2,832 ± 179 | 24 ± 3 | 33 ± 5 |
| pREJO4541 | B | 57,733 ± 3,229 | 10,129 ± 1,086 | 9 ± 4 | 8 ± 1 |
| SF162 | B | 26,503 ± 3,030 | 5,138 ± 613 | 27 ± 4 | 26 ± 9 |
| JRFL | B | 8,998 ± 855 | 1,756 ± 96 | 39 ± 5 | 74 ± 21 |
| SC422661.8 | B | 16,473 ± 3,788 | 17,481 ± 2,084 | 29 ± 5 | 7 ± 1 |
| AC10.0.29 | B | 3,496 ± 970 | 1,092 ± 170 | 6 ± 2 | 9 ± 2 |
| TRO.11 | B | 6,175 ± 620 | 3,095 ± 476 | 26 ± 3 | 27 ± 6 |
| X2278_C2_B6 | B | 5,986 ± 447 | 1,665 ± 275 | 13 ± 1 | 11 ± 3 |
| B01 | B′ | 89,185 ± 6,922 | 8,630 ± 1,053 | 76 ± 7 | 93 ± 6 |
| B02 | B′ | 9,283 ± 2,120 | 975 ± 60 | 23 ± 2 | 29 ± 5 |
| B04 | B′ | 5,355 ± 568 | 1,272 ± 117 | 23 ± 6 | 44 ± 3 |
| 43-22 | B′ | 30,648 ± 2,054 | 1,354 ± 662 | 5 ± 1 | 8 ± 2 |
| Du156 | C | 14,433 ± 2,125 | 10,538 ± 724 | 6 ± 0 | 8 ± 1 |
| ZM53 M.PB12 | C | 25,809 ± 8,710 | 4,221 ± 715 | 21 ± 2 | 19 ± 3 |
| CAP210.2.00.E8 | C | 140,667 ± 16,565 | 29,190 ± 2,347 | 35 ± 2 | 62 ± 7 |
| CAP45.2.00.G3 | C | 141,963 ± 25,069 | 19,025 ± 4,703 | 9 ± 1 | 12 ± 3 |
| CE703010217_B6 | C | 41,847 ± 1,094 | 3,618 ± 83 | 27 ± 2 | 20 ± 2 |
| HIV_25710-2.43 | C | 13,974 ± 1,841 | 4,662 ± 271 | 26 ± 3 | 27 ± 3 |
| CE1176_A3 | C | 8,608 ± 5,859 | 1,422 ± 275 | 10 ± 2 | 15 ± 1 |
| X1632-S2-B10 | G | 12,240 ± 2,860 | 2,034 ± 404 | 19 ± 2 | 32 ± 7 |
| 246_F3_C10_2 | A/C | 39,126 ± 4,633 | 6,620 ± 2,366 | 20 ± 5 | 26 ± 2 |
| AE03 | A/E | 9,671 ± 2,403 | 3,367 ± 429 | 16 ± 3 | 17 ± 4 |
| GX11.13 | A/E | 22,219 ± 11,067 | 1,892 ± 933 | 10 ± 1 | 14 ± 1 |
| SHX335.24 | A/E | 48,420 ± 7,568 | 25,968 ± 4,444 | 11 ± 1 | 16 ± 3 |
| CNE8 | A/E | 29,069 ± 7,541 | 3,612 ± 133 | 40 ± 3 | 31 ± 1 |
| CNE55 | A/E | 21,888 ± 3,389 | 2,425 ± 449 | 14 ± 1 | 8 ± 1 |
| CH64.20 | B/C | 31,270 ± 20,276 | 4,358 ± 1,080 | 27 ± 2 | 29 ± 3 |
| CH070.1 | B/C | 163,316 ± 6,269 | 6,269 ± 2,286 | 37 ± 5 | 38 ± 6 |
| CH110 | B/C | 33,790 ± 2,139 | 3,631 ± 964 | 6 ± 1 | 8 ± 1 |
| CH119.10 | B/C | 17,993 ± 5,279 | 2,210 ± 21 | 19 ± 2 | 11 ± 2 |
| CH120.6 | B/C | 51,541 ± 27,076 | 4,591 ± 628 | 18 ± 2 | 19 ± 2 |
| BJOX002000.03.2 | B/C | 33,007 ± 18,876 | 4,923 ± 1,363 | 36 ± 3 | 31 ± 4 |
| Mean | 36,020 | 5,994 | 22 | 26 | |
a
The assay was performed in triplicate and was repeated three times.